Fate, U Minn in immunotherapy deal

Fate Therapeutics Inc. (NASDAQ:FATE) partnered with the University of Minnesota to develop NK cell-based off-the-shelf immunotherapies for cancer. The deal combines the university's technology to produce persistent NK cells with Fate's cell programming capabilities.

The collaboration will focus on two NK cell-based programs at the university. One program aims to develop an NK cell therapeutic for use in combination with tumor-specific monoclonal antibodies. The other program involves differentiating and genetically modifying NK cells from induced pluripotent stem (iPS) cells. ...